This article is more than 5 years old. Information may no longer be current.

Bioventus announces agreement to continue distribution of five-injection HA product for knee OA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bioventus announced it has extended its agreement with Seikagaku Corporation to continue distributing the five-injection, hyaluronic acid product Supartz FX in the United States until May 2028.

According to a press release Bioventus will be the exclusive U.S. distributor of Supartz FX, which is used to treat pain associated with knee osteoarthritis.

“We are pleased Supartz FX will remain in the Bioventus portfolio, along with three-injection [hyaluronic acid] HA Gelsyn-3 and Durolane, our single-injection HA, for many years to come,” Tony Bihl, CEO of Bioventus, said in the release. “Joint fluid treatments safely manage knee OA pain allowing people to resume active lives and we believe our complement of HA offerings is unmatched in meeting the varied needs of patients, physicians and payers in the U.S. This is consistent with our strategy to be a market-leading biologics company in treatments for OA.”

Reference:

www.bioventusglobal.com